The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics • A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation • Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies? • Breathing Engineered Bacteria: A New Approach to Treating Lung Disease • Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data • Breathing Engineered Bacteria: A New Approach to Treating Lung Disease

Editor's Choice

All Editor's Choice →
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
 Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

Caelus welcomes the publication by the European Food Safety Authority (EFSA) of its scientific opinion on the safety of gut bacterium Anaerobutyricum soehngenii CH106 (A. soehngenii) for use in food

BY Microbiome Times · SEP 1, 2026 · 3 MIN READ
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026
LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
Editor's Choice

LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis

MAY 1, 2026